Background. Due to the unfavorable prognosis in type 2 diabetes mellitus (DM2), priority is given to prescribing hypoglycemic drugs that not only provide optimal glycemic control, but also have pleiotropic effects.
Objective. Evaluation of the non-glycemic benefits of using a fixed combination (FC) of alogliptin and pioglitazone in real clinical practice in diabetic patients who have not achieved carbohydrate metabolism compensation with metformin monotherapy.
Methods. Thirty DM2 patients were examined, including 18 men and 12 women, aged 22 to 72 years (mean age 50.9±11.4 years). Anthropometric parameters, glycated hemoglobin levels, fasting plasma glucose, postprandial glucose, lipid spectrum parameters were assessed; glomerular filtration rate (GFR) and the liver fibrosis index were calculated. The analyzed parameters were recorded initially and 6 months after adding of FC alogliptin 25 mg and pioglitazone 30 mg to metformin (average dose 2000 mg/day).
Results. After 6 months, treatment with FC of alogliptin and pioglitazone resulted in an effective decrease in glycemic control and peripheral tissue insulin resistance, favorable changes in lipid metabolism with a positive effect on the calculated liver fibrosis index and GFR levels.
Conclusion. FC of alogliptin and pioglitazone not only provide optimal glycemic control, but also is capable of exerting a number of pleiotropic effects on cardiovascular diseases and non-alcoholic fatty liver disease.

Keywords: alogliptin, pioglitazone, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, type 2 diabetes mellitus